145 related articles for article (PubMed ID: 37727346)
1. Malignancy risk in Bethesda class IV thyroid nodules in an iodine deficient region.
Loderer T; Bonati E; Donato V; Viani L; Cozzani F; Del Rio P
Gland Surg; 2023 Jul; 12(7):884-893. PubMed ID: 37727346
[TBL] [Abstract][Full Text] [Related]
2. Rates of Malignancy in Cytology Indeterminate Thyroid Nodules: A Single Center Surgical Series.
Baraf L; Avidor Y; Bahat Dinur A; Yoel U; Samueli B; Joshua BZ; Fraenkel M
Isr Med Assoc J; 2023 Feb; 25(2):147-151. PubMed ID: 36841986
[TBL] [Abstract][Full Text] [Related]
3. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
4. Thyroid nodules with indeterminate cytology: association between nodule size, histopathological characteristics and clinical outcome in differentiated thyroid carcinomas - a multicenter retrospective cohort study on 761 patients.
Cozzani F; Bettini D; Rossini M; Bonati E; Nuzzo S; Loderer T; Pedrazzi G; Zaccaroni A; Del Rio P
Updates Surg; 2021 Oct; 73(5):1923-1930. PubMed ID: 34100186
[TBL] [Abstract][Full Text] [Related]
5. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
6. USING THE ATA AND ACR TI-RADS SONOGRAPHIC CLASSIFICATIONS AS ADJUNCTIVE PREDICTORS OF MALIGNANCY FOR INDETERMINATE THYROID NODULES.
Ahmadi S; Herbst R; Oyekunle T; Jiang X'; Strickland K; Roman S; Sosa JA
Endocr Pract; 2019 Sep; 25(9):908-917. PubMed ID: 31170369
[No Abstract] [Full Text] [Related]
7. Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review.
Hier J; Avior G; Pusztaszeri M; Krasner JR; Alyouha N; Forest VI; Hier MP; Mlynarek A; Richardson K; Sadeghi N; Tamilia M; Payne RJ
J Otolaryngol Head Neck Surg; 2021 Apr; 50(1):29. PubMed ID: 33910629
[TBL] [Abstract][Full Text] [Related]
8. Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery.
Lindeman BM; Nehs MA; Angell TE; Alexander EK; Gawande AA; Moore FD; Doherty GM; Cho NL
Ann Surg Oncol; 2019 Jan; 26(1):93-97. PubMed ID: 30341576
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Lobectomy for Bethesda III Thyroid Nodules: Pathological Outcomes and Risk Factors for Malignancy.
Walters BK; Garrett SL; Aden JK; Williams GM; Butler-Garcia SL; Newberry TR; Mckinlay AJ
Ann Otol Rhinol Laryngol; 2021 Sep; 130(9):1064-1068. PubMed ID: 33567896
[TBL] [Abstract][Full Text] [Related]
10. Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF
Chirayath SR; Pavithran PV; Abraham N; Nair V; Bhavani N; Kumar H; Menon UV; Menon AS
Indian J Endocrinol Metab; 2019; 23(3):278-281. PubMed ID: 31641627
[TBL] [Abstract][Full Text] [Related]
11. An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules.
Taccogna S; Papini E; Novizio R; D'Angelo M; Turrini L; Persichetti A; Pontecorvi A; Guglielmi R
Front Endocrinol (Lausanne); 2022; 13():1078019. PubMed ID: 36531453
[TBL] [Abstract][Full Text] [Related]
12. Additional Surgery for Occult Risk Factors After Lobectomy in Solitary Thyroid Nodules is Predicted by Cytopathology Classification and Tumor Size.
Flagg A; Rooper L; Sheth S; Shaear M; Santhanam P; Prescott J; Olson MT; Bishop JA; Mammen JS
Endocr Pract; 2020 Jul; 26(7):754-760. PubMed ID: 33471644
[TBL] [Abstract][Full Text] [Related]
13. Need for Completion Thyroidectomy in Patients Undergoing Lobectomy for Indeterminate and High-Risk Nodules: Impact of Intra-Operative Findings and Final Pathology.
Moore EC; Zolin S; Krishnamurthy V; Jin J; Shin J; Berber E; Siperstein A
World J Surg; 2020 Feb; 44(2):408-416. PubMed ID: 31531727
[TBL] [Abstract][Full Text] [Related]
14. Can Cytologic and Sonographic Features Help Prevent Overtreatment of Bethesda V Thyroid Nodules?
Higgins S; James BC; Sacks B; Mowschenson P; Nishino M; Hasselgren PO
J Surg Res; 2021 Dec; 268():112-118. PubMed ID: 34298210
[TBL] [Abstract][Full Text] [Related]
15. ThyroSeq
Rivas AM; Nassar A; Zhang J; Casler JD; Chindris AM; Smallridge R; Bernet V
Endocr Pract; 2018 Sep; 24(9):780-788. PubMed ID: 30084677
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ultrasound-guided microwave ablation versus surgical resection for Bethesda category IV thyroid nodules: A retrospective comparative study.
Yang J; Zhang Y; Li X; Zhao Y; Han X; Chen G; Chu X; Li R; Wang J; Huang F; Liu C; Xu S
Front Endocrinol (Lausanne); 2022; 13():924993. PubMed ID: 36213294
[TBL] [Abstract][Full Text] [Related]
17. Thyroid Nodule Management: Thyroid-Stimulating Hormone, Ultrasound, and Cytological Classification System for Predicting Malignancy.
Al Dawish MA; Alwin Robert A; Thabet MA; Braham R
Cancer Inform; 2018; 17():1176935118765132. PubMed ID: 29581701
[TBL] [Abstract][Full Text] [Related]
18. The role of thyroid sonographic malignancy risk features when the fine needle aspiration biopsy result is indeterminate.
Kotecka-Blicharz A; Krzempek M; Cortez AJ; Oczko-Wojciechowska M; Czarniecka A; Nożyńska E; Chmielik E; Jarząb B; Krajewska J
Endokrynol Pol; 2022; 73(2):316-324. PubMed ID: 35593681
[TBL] [Abstract][Full Text] [Related]
19. Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules.
Valderrabano P; Khazai L; Thompson ZJ; Otto KJ; Hallanger-Johnson JE; Chung CH; Centeno BA; McIver B
JAMA Otolaryngol Head Neck Surg; 2018 Sep; 144(9):788-795. PubMed ID: 30027226
[TBL] [Abstract][Full Text] [Related]
20. Malignancy Rates in Thyroid Nodules Classified as Bethesda Categories III and IV: Retrospective Data from a Tertiary Center.
Godoi Cavalheiro B; Kober Nogueira Leite A; Luongo de Matos L; Palermo Miazaki A; Marcel Ientile J; Aurelio V Kulcsar M; Roberto Cernea C
Int J Endocrinol Metab; 2018 Jan; 16(1):e12871. PubMed ID: 29696036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
